The safety of treatments for angioedema with hereditary C1 inhibitor deficiency
| Autor: | Marco Cicardi, Marta Mansi, Arnaldo Andreoli, Maddalena Alessandra Wu, Andrea Zanichelli |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Abdominal pain
medicine.medical_specialty Time Factors Bradykinin C1-inhibitor chemistry.chemical_compound Ecallantide Icatibant medicine Animals Humans Pharmacology (medical) Angioedema biology business.industry Angioedemas Hereditary General Medicine respiratory system bacterial infections and mycoses medicine.disease Dermatology respiratory tract diseases Review article Abdominal Pain chemistry Anesthesia Hereditary angioedema biology.protein medicine.symptom business Complement C1 Inhibitor Protein medicine.drug |
| Zdroj: | Expert opinion on drug safety. 14(11) |
| ISSN: | 1744-764X |
| Popis: | Angioedema is a localized and self-limiting edema of the subcutaneous and submucosal tissue. Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is the best characterized form of hereditary angioedema. In C1-INH-HAE, the reduced plasma levels of C1-INH cause instability of the contact system with release of bradykinin, the key mediator of angioedema. C1-INH-HAE is characterized by recurrent skin swelling, abdominal pain, and potentially life-threatening upper airways obstruction. Knowledge of the molecular mechanisms leading from C1-INH deficiency to angioedema allowed the development of several therapies.The aim of this review article is to discuss the safety of currently available treatments of C1-INH-HAE. The authors give an insight on the mechanism of action and safety profile of drugs for treatment of acute attacks and for short- and long-term prophylaxis. Evidence from systematic reviews, clinical trials, retrospective studies, and case reports is summarized in this review.C1-INH-HAE is a disabling, life-threatening condition that lasts life-long. Different therapeutic approaches with different drugs provide significant benefit to patients. Safety profiles of these therapies are critical for optimal therapeutic decision and need to be known by C1-INH-HAE treating physicians for appropriate risk/benefit evaluation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|